This report was first published by Endpoints News. To see the original version, click here
Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies.
The company reported in a pipeline update Tuesday that it ended a Phase 2 program of maplirpacept in patients with hematological malignancies. A spokesperson confirmed there were no additional ongoing studies testing drugs originating from Trillium, acquired by Pfizer in 2021 for roughly $2.25 billion.
您已阅读23%（578字），剩余77%（1926字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。